title: Pleiotropic preconditioning-like cardioprotective effects of hypolipidemic drugs in acute ischemia-reperfusion in normal and hypertensive rats.
abstract: Although pleiotropy, which is defined as multiple effects derived from a single gene, was recognized many years ago, and considerable progress has since been achieved in this field, it is not very clear how much this feature of a drug is clinically relevant. During the last decade, beneficial pleiotropic effects from hypolipidemic drugs (as in, effects that are different from the primary ones) have been associated with reduction of cardiovascular risk. As with statins, the agonists of peroxisome proliferator-activated receptors (PPARs), niacin and fibrates, have been suggested to exhibit pleiotropic activity that could significantly modify the outcome of a cardiovascular ailment. This review examines findings demonstrating the impacts of treatment with hypolipidemic drugs on cardiac response to ischemia in a setting of acute ischemia-reperfusion, in relation to PPAR activation. Specifically, it addresses the issue of susceptibility to ischemia, with particular regard to the preconditioning-like cardioprotection conferred by hypolipidemic drugs, as well as the potential molecular mechanisms behind this cardioprotection. Finally, the involvement of PPAR activation in the mechanisms of non-metabolic cardioprotective effects from hypolipidemic drugs, and their effects on normal and pathologically altered myocardium (in the hearts of hypertensive rats) is also discussed.
authors.affiliation: a Institute for Heart Research, Slovak Academy of Sciences and Centre of Excellence of SAS NOREG, POB 104, Dúbravská cesta 9, 840 05 Bratislava, Slovak Republic.
authors.forename: Táňa
authors.initials: T
authors.lastname: Ravingerová
authors.affiliation: a Institute for Heart Research, Slovak Academy of Sciences and Centre of Excellence of SAS NOREG, POB 104, Dúbravská cesta 9, 840 05 Bratislava, Slovak Republic.
authors.forename: Veronika
authors.initials: V
authors.lastname: Ledvényiová-Farkašová
authors.affiliation: a Institute for Heart Research, Slovak Academy of Sciences and Centre of Excellence of SAS NOREG, POB 104, Dúbravská cesta 9, 840 05 Bratislava, Slovak Republic.
authors.forename: Miroslav
authors.initials: M
authors.lastname: Ferko
authors.affiliation: a Institute for Heart Research, Slovak Academy of Sciences and Centre of Excellence of SAS NOREG, POB 104, Dúbravská cesta 9, 840 05 Bratislava, Slovak Republic.
authors.forename: Monika
authors.initials: M
authors.lastname: Barteková
authors.affiliation: b Institute of Normal and Pathological Physiology, Slovak Academy of Sciences and Centre of Excellence of SAS NOREG, Bratislava, Slovak Republic.
authors.forename: Iveta
authors.initials: I
authors.lastname: Bernátová
authors.affiliation: b Institute of Normal and Pathological Physiology, Slovak Academy of Sciences and Centre of Excellence of SAS NOREG, Bratislava, Slovak Republic.
authors.forename: Ol'ga
authors.initials: O
authors.lastname: Pecháňová
authors.affiliation: c Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic.
authors.forename: Adriana
authors.initials: A
authors.lastname: Adameová
authors.affiliation: d Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
authors.forename: František
authors.initials: F
authors.lastname: Kolář
authors.affiliation: e School of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
authors.forename: Antigone
authors.initials: A
authors.lastname: Lazou
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D019157:Ischemic Preconditioning, Myocardial; D050356:Lipid Metabolism / Q000187:drug effects; D015428:Myocardial Reperfusion Injury / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D047492:Peroxisome Proliferator-Activated Receptors / Q000378:metabolism*; D051381:Rats
chemical_list: D002316:Cardiotonic Agents; D000960:Hypolipidemic Agents; D047492:Peroxisome Proliferator-Activated Receptors
keywords: PPARα activation; activation des PPARα; acute myocardial ischemia–reperfusion; effets pléiotropiques; hypolipidemic drugs; ischémie aiguë–reperfusion du myocarde; médicaments hypolipidémiants; pleiotropic effects